Micro- and macrovascular abnormalities in systemic sclerosis by Hettema, Martha Elisabeth
  
 University of Groningen
Micro- and macrovascular abnormalities in systemic sclerosis
Hettema, Martha Elisabeth
IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from
it. Please check the document version below.
Document Version
Publisher's PDF, also known as Version of record
Publication date:
2008
Link to publication in University of Groningen/UMCG research database
Citation for published version (APA):
Hettema, M. E. (2008). Micro- and macrovascular abnormalities in systemic sclerosis. s.n.
Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the
author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).
Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the















IMPAIRED MICROVASCULAR REACTIVITY IN 
PATIENTS WITH SYSTEMIC SCLEROSIS IS DUE TO 


































Objective: To assess endothelial function at the level of skin microvasculature in patients 
with systemic sclerosis (SSc). Furthermore, to evaluate whether microvascular reactivity is 
related to the disease or traditional cardiovascular risk factors. 
Methods: Microvascular skin reactivity was assessed using a combination of laser Doppler 
fluxmetry (LDF) and iontophoretic administration of acetylcholine (ACh, endothelium-
dependent vasodilator) and sodium nitroprusside (SNP, endothelium-independent 
vasodilator) in 47 SSc patients and 23 healthy controls. Traditional risk factors for 
cardiovascular disease and serum markers for endothelial activation were determined. 
Results: Median (interquartile ranges) ACh-mediated vasodilation, expressed as a 
percentage increase in flux, was significantly decreased in SSc patients compared to 
controls (168% (68-288) versus 596% (303-899), p<0.001), as was SNP-mediated 
vasodilation (165% (69-343) versus 443% (250-831), p=0.001). Impaired Ach-mediated 
vasodilation was found also after adjustment for confounders in a linear regression analysis 
(p=0.003), but impaired SNP-mediated vasodilation in SSc patients was not statistically 
significant anymore after adjustment for confounders (p=0.076).  
Conclusion: This study demonstrates impaired endothelium-dependent vasodilation in SSc 
patients, also after adjustment for cardiovascular risk factors. Besides endothelial 
dysfunction, structural defects may also present in the microcirculation of SSc patients 
since we demonstrated a tendency to impaired endothelium-independent vasodilation.  
 







Systemic sclerosis (SSc) is a systemic autoimmune disease characterized by immunologic 
abnormalities, fibrosis of the skin and internal organs, and widespread vascular 
involvement. Vascular or endothelial cell dysfunction has been suggested to be a crucial 
element in the pathogenesis of SSc,
1-3
 suggested by, amongst others, the presence of 
Raynaud‟s phenomenon (RP) in allmost all patients, digital ulcers and nailfold 
capillaroscopic abnormalities. Several non-invasive techniques are available for the 
assessment of endothelial cell dysfunction. Laser Doppler fluxmetry combined with 
iontophoresis of vasoactive agents provides a noninvasive method to assess endothelium-
dependent and endothelium-independent vasodilator responses of the microcirculation.
4;5
 
Skin fibrosis was found not to interfere with iontophoretical diffusion of vasoactive drugs 
across the skin in SSc patients compared with healthy controls, although, as expected, 
impaired vasodilator responses were observed. 
6
 Until now, different protocols studying 
endothelial cell dysfunction in SSc patients have been used with conflicting results. In 
general, these studies showed impaired endothelium-dependent and endothelium-
independent vasodilation in patients with SSc, the endothelium-dependent vasodilation 
being most affected.
6-11
 Endothelial cell dysfunction has also been found in patients with 
classical traditional risk factors like hypertension, diabetes mellitus and obesity.
4;5;12-16
 
Therefore, the aim of our study was to assess endothelial microvascular function in patients 
with SSc in comparison to healthy control subjects, and to relate the results to possible 




MATERIALS AND METHODS 
 
Patients 
From November 2005 to May 2006, 47 consecutive SSc patients from our out-patient clinic 
were included. Patients with SSc were classified according to the ACR criteria
17
 and were 
subclassified in subsets as defined by LeRoy et al.
18;19
 Disease activity was assessed by the 
preliminary European Scleroderma Study Group (EScSG) activity indices (a score ranging 
from 0-10). A score higher than 3 denotes active disease.
20;21
 Also, the revised preliminary 
SSc severity scale (Medsger‟s severity scale), a measure of activity, damage and severity, 
was used. This scale is a 9-organ disease severity scale in which for each organ system a 
score of 0 to 4 is applied, with 0 being normal and 4 denoting endstage organ 
involvement.
22
 Pregnancy and diabetes mellitus were exclusion criteria. Healthy subjects in 
the same age decade were included as controls. Ethical approval for the study was obtained 
from the Medical Ethical Committee of the University Medical Center Groningen. 
Informed consent was obtained from each participant. 
 Data were obtained from all subjects with respect to traditional risk factors for 
cardiovascular disease (CVD), including body mass index (BMI), smoking status, blood 
pressure, lipid levels and family history of CVD (considered positive if first-degree 
relatives suffered from CVD before the age of 60 years). Sitting blood pressure was 





Laser Doppler fluxmetry in combination with iontophoresis 
Skin perfusion was measured by a Periflux 4000 laser Doppler system in combination with 
a Periflux tissue heater (PF4005, Peritemp; all equipment from Perimed, Stockholm, 
Sweden) set to 31 ºC. The measurements were performed between 8:00 am and 5:00 pm in 
a quiet room with a temperature of approximately 24 ºC. Caffeine-containing drinks or 
smoking were not allowed from 12 hours before the test. A special iontophoresis probe 
(PF481-2, Perimed, Stockholm, Sweden) containing a thermostatic probe holder was placed 
on the dorsal side of the middle phalanx of the third finger. A battery-powered 
iontophoresis controller (Perilont 382, Perimed, Stockholm, Sweden) was used to provide a 
direct current for drug iontophoresis. Iontophoresis is a non-invasive method of introducing 
charged substances across the surface of the skin by means of a small direct electric current. 
Iontophoresis of acetylcholine (ACh, 1%, Miochol, IOLAB, Bourneville Pharma, The 
Hague, the Netherlands) induces vascular smooth muscle relaxation indirectly via nitric 
oxide (NO) release and is considered an endothelium-dependent vasodilator. Iontophoresis 
of sodium nitroprusside (SNP, 0,1%, dissolved in NaCl 0,9%), a NO donor, evokes 
vasodilation by directly increasing cyclic guanosine monophosphate (cGMP) in vascular 
smooth muscle cells, and is considered an endothelium-independent vasodilator. We 
followed the same protocol as decribed previously.
23;24
 ACh was delivered with an anodal 
current; seven doses (0.1 mA for 20 s) were delivered, with a 60-second interval between 
each dose. SNP was delivered using a cathodal current; nine doses (0,2 mA for 20 s) were 
delivered, with a 90-second interval between each dose. The mean flux of the first 5 
minutes excluding moving artefacts made up the baseline flux. The plateau flux was 
defined as the mean flux during the last 2 minutes of the plateau phase. Absolute increase 
was defined as the difference between plateau flux and baseline flux. Relative increase 
(vasodilation) was defined as the ratio of absolute increase and baseline flux. This protocol 
gave intraindividual coefficients of variation for maximal responses of 16% for ACh and 





Lipid levels were measured by routine techniques. Total cholesterol, triglycerides and 
HDL-cholesterol were determined by enzymatic methods on a Vitros 950 (Ortho-Clinical 
Diagnostics, Rochester NY, USA). HDL-cholesterol was isolated by precipitation of LDL-
cholesterol and VLDL with phosphotungstate and magnesiumchloride. Serum LDL-
cholesterol was calculated using the Friedewald formula, excluding patients with 
triglycerides levels above 5.0 mmol/l. 
Additional serum and plasma samples for determination of markers of endothelial 
activation were stored at -20ºC until analysis. Serum levels of vascular cell adhesion 
molecule-1 (s-VCAM-1, R&D Systems, Abingdon, UK) and thrombomodulin (TM, 
Diaclone, Besançon, France) were measured according to the manufacturer‟s instruction. 
Von Willebrand factor (vWF) was determinded using in-house enzyme linked 





Because of a low percentage of diffuse cutaneous SSc (dSSc) in our patient group, the 2 
subsets were taken together in the analysis. Data are expressed as mean ± SD or median 





(interquartile range) unless stated otherwise. Differences between patients and controls 
were assessed by Student‟s t-test, by Mann-Whitney-U, and by X2 as appropriate. The 
correlation between endothelial-dependent and endothelial-independent vasodilation and 
disease related variables was assessed by Pearson correlation coefficient or by Spearman 
correlation coefficient as appropriate. Multiple regression analysis was used to assess the 
relationship between vasodilator responses, the presence of SSc, and demographic and 
clinical characteristics. An unadjusted analysis in which no corrections were made for 
confounders, and an adjusted analysis in which corrections were made for confounders are 
presented. A variable was defined to be a confounder when significantly changing the 
regression coefficient B in the model testing the assocoiation between patient category (SSc 
patients and healthy controls) and vasodilator response (ACh-medited vasodilation and 
SNP-mediated vasodilation). Due to lack of normal distribution of residuals in the model, 
ACh-mediated and SNP-mediated vasodilation values had to be transformed by using the 
natural logarithm of these values +1. The variables age, gender and BMI were also studied 
as a potential effect modifier in the relationship of interest. A 2-tailed p-value of <0.05 was 
considered significant. All analyses were carried out with the Statistical Package of Social 





Characteristics of patients and controls 
Clinical characteristics of the subjects are presented in table 1. A total of 47 patients (7 
males, 40 females) with SSc participated in the study, with a mean age of 55 years (± 12 
years). Limited cutaneous SSc (lcSSc) was present in 43 (91%) and diffuse cutaneous SSc 
(dcSSc) in 4 (9%) patients. Patients with SSc had a median disease duration of 7 years (IQR 
3-12) and had experienced Raynaud‟s phenomenon (RP) for almost 12 years (IQR 6-25). 
The median Rodnan Skin Score was 6.0 (IQR 4.0-13.0), the preliminary European 
Scleroderma Study Group activity index (EScSG) was 0.5 (IQR 0.5-1.5) and the Medsger‟s 
severity Scale was 6.0 (IQR 5.0-7.0). The 23 healthy controls were younger (mean age 48 ± 
10 years, p=0.012) than SSc patients. Patients and controls were similar with respect to 
current smoking habits (6% vs 0%, p=n.s.), but were different regarding former smoking 
habits. No differences were seen in family history of CVD, but patients had a higher 
prevalence of treated hypertension. No differences were present in systolic and diastolic 
blood pressures between patients and controls. However, antihypertensive medication or 
vasodilating drugs for Raynaud‟s phenomenon were significantly more frequently used in 
SSc patients in comparison with controls. Patients had also lower HDL-cholesterol and 
higher triglycerides levels than healthy controls. No differences were found in levels of 
















Gender, male sex (n (%)) 3 (13) 7 (15) 
Age (years) 48 ± 10 55 ± 12 
Ever smoking (n (%))    1 (4) 23 (49)* 
Family history CVD (n (%)) 4 (17) 10 (21) 
Treated hypertension 0 (0) 11 (23) 
SBP (mm Hg) 120 (110-125) 120 (110-135) 
DBP (mm Hg) 78 (72-81) 75 (70-80) 
Antihypertensive or vasodilating medication (n (%)) 
   Calcium channel blockers (n (%)) 
   Angiotensin converting enzyme inhibitors (n (%)) 









BMI (kg/m 2) 23.3 ± 2.5 23.7 ± 2.9 
Total cholesterol (mmol/l) 5.16 ± 0.88 5.29 ± 0.96 
HDL-cholesterol (mmol/l) 1.84 (1.58-2.07) 1.40 (1.23-1.83)* 
LDL-cholesterol (mmol/l) 2.74 ± 0.92 3.09 ± 0.82 
Triglycerides (mmol/l) 0.94 (0.71-1.31) 1.36 (1.17-2.14)* 
Statins (n (%)) 0 (0) 5 (11) 
VCAM-1 (ng/ml) 275 ± 59 254 ± 89 
vWF (%) 58 (46-101) 73 (31-125) 
TM (ng/ml) 2.8 (2.1-3.7) 3.8 (2.4-5.0) 
SSc, systemic sclerosis; CVD, cardiovascular disease; DM, diabetes mellitus; BMI, body mass index; SBP, systolic blood pressure; 
DBP, diastolic blood pressure; HDL, high-density lipoprotein; LDL, low-density lipoprotein; VCAM-1: vascular cell adhesion 
molecule-1; vWF: von Willebrand factor; TM: thrombomodulin 
Unless stated otherwise, values are expressed as mean ± standard deviation when normally distributed and as median (interquartile 
range) when non-normally distributed  * p 0.05 
 
Vascular responses 
Responses to ACh and SNP are shown in table 2 and figures 1-2. Baseline flux did not 
differ significantly between SSc patients and controls. In SSc patients a significantly 
reduced ACh-mediated (p<0.001) and SNP-mediated vasodilation (p=0.001) were present 




























plateau flux (PU) 155 (96-219) 61 (31-113)* 
absolute increase (PU) 113 (82-176) 33 (13-64)* 
ACh-mediated vasodilation (%) 596 (303-899) 168 (68 -282)* 
Sodium nitroprusside 





plateau flux (PU) 112 (80-151) 67 (34-85)* 
absolute increase (PU) 92 (54-117) 29 (15-65)* 
SNP-mediated vasodilation (%) 443 (250-831) 165 (69-343)* 
SSc, systemic sclerosis; PU, arbitrary units of flux; Ach, acetylcholine; SNP, sodium nitroprusside 




Figure 1. Acetylcholine-mediated vasodilation in 
patients with systemic sclerosis (▲) and controls (•). 
Bars represent median values. * p<0.01 versus 
controls. 
 
Figure 2. Sodium nitroprusside-mediated vasodilation 
in patients with systemic sclerosis (▲) and controls (•). 









































































Since baseline characteristics between SSc patients and controls were not similar 
(table 1), we conducted a linear regression analysis with (the transformed value of) ACh-
mediated vasodilation and SNP-mediated vasodilation as dependent variables (Table 3). 
The adjusted model, corrected for ever smoking, use of antihypertensive medication and 
age as confounders, revealed that the difference in ACh-mediated vasodilation between SSc 
patients and healthy controls was explained just by the presence of SSc (p=0.003). The 
association between SSc and SNP-mediated vasodilation was not statistically significant 
(p=0.076) after correction for HDL cholesterol, use of antihypertensive medication and age 
as confounders. For both ACh-mediated vasodilation and SNP-mediated vasodilation no 
correction for the other parameters (BMI, gender, LDL cholesterol, total cholesterol and 
triglycerides) was necessary, since these outcome parameters were no confounders in the 
model. No effect modification by age, gender or BMI was found either. 
In patients an inverse correlation ( = -0.338, p=0.027) was found for ACh-
mediated vasodilation and modified Rodnan Skin Score, suggesting a more impaired 
vasodilation with increasing stiffness of the skin. No such correlation was found for other 
disease related factors in ACh-mediated vasodilation or SNP-mediated vasodilation (Table 
4). Also, no correlation was found between ACh-mediated vasodilation or SNP-mediated 
vasodilation and endothelial activation markers (data not shown). 
 
 
Table 3 Linear regression analysis for a) endothelium-dependent (ACh-mediated) vasodilation and b) 
endothelium-independent (SNP-mediated) vasodilation in SSc patients and healthy controls 
a) 
Group (patients, controls) B# 95% confidence interval p-value 
Unadjusted/crude 1.393 0.677; 2.109 <0.001 
Adjusted* 1.632 0.494; 2.771 0.006 
The natural logarithm of ACh-mediated vasodilation +1 was used as dependent variable as using ACh-mediated 
vasodilation showed non-normal distribution of residuals in the linear regression model. 
* In the adjusted models corrections were made for the confounders age, ever smoking and use of 
antihypertensive; a total of 68 patients and controls were available for this analysis 
# B is the regression coefficient  
 
b) 
Group (patients, controls) B# 95% confidence interval p-value 
Unadjusted/crude 1.087 0.510; 1.665 <0.001 
Adjusted* 0.851 -0.090; 1.792 0.076 
The natural logarithm of SNP-mediated vasodilation +1 was used as dependent variable as using NP-mediated 
vasodilation showed non-normal distribution of residuals in the linear regression model. 
In the adjusted models corrections were made for the confounders age, ever smoking and use of antihypertensive; 
a total of 60 patients and controls were available for this analysis 









Table 4. Correlations between acetylcholine- and sodium nitroprusside-mediated vasodilation and disease related 
variables 
 ACh SNP 
 ρ p-value ρ p-value 
Disease duration 0.158 0.289 -0.086 0.568 
Duration Raynaud‟s phenomenon 0.008 0.956 -0.011 0.941 
Modified Rodnan Skin Score -0.338 0.027 -0.152 0.331 
Medsger‟s severity score -0.265 0.086 -0.131 0.403 
EScSG activity index -0.245 0.097 -0.190 0.201 
Cumulative prednisolone dose 0.074 0.764 -0.128 0.601 






The present study demonstrates, as expected, impaired endothelium-dependent responses in 
patients with SSc compared to healthy controls. These decreased endothelium-dependent 
responses were present even after adjustment of confounders, known for their influence on 
microvascular reactivity. Endothelium-independent responses in SSc patients were 
impaired, yet not statistically significant after adjustment of confounders.  
Endothelial dysfunction is thought to be crucial in the pathogenesis of SSc. 
Previous studies, using different techniques and protocols, showed conflicting results, but, 
in general, impaired endothelial-dependent and endothelial-independent vasodilatation was 
observed.
6-11;26-28
 However, few of these studies mentioned baseline characteristics besides 
age and gender, and when mentioned, results of microvascular reactivity were not corrected 
for possible confounders.  
Our results are in agreement with previous studies in SSc using the same 
6;11
 or a 
different non-invasive method.
26-29
 After adjustment for possible confounders we still found 
a difference in endothelial-dependent vasodilation between patients and healthy controls. In 
contrast to our results, Anderson et al. did not find differences in vascular reactivity in 
patients with SSc and primary Raynaud‟s phenomenon measured in forearm skin7 and 
digital skin,
8
 using laser Doppler fluxmetry in combination with iontophoresis. As stated 
before, these differences can be explained by the non-invasive method used, but also by 
differences in dermal site or iontophoresis protocol. We used the same concentration of 
ACh but a lower concentration of SNP compared to the studies mentioned above. Also 
differences were present in iontophoretic currents, frequency and interval between each 
dose. In our protocol iontophoresis was started by setting time and current strength based 
on previously documented and accepted protocols of multiple fixed dosages.
4;5;16;30
  
Our results are in agreement with the observation that endothelial abnormalities 
are found in patients with early SSc. 
31
 We expected to find endothelial abnormalities since 
our patients had a median disease duration of 6 years. The impaired vasodilatory response 
to ACh reflects endothelial dysfunction. For endothelial-independent vasodilation no 
functioning endothelium is required, since SNP is a donor of NO, normally produced by the 





analysis, looking at the p-value found and the relatively low number of participants, we 
cannot rule out that there is a structural or functional abnormality of the smooth muscle of 
the arteriolar wall.  
An unavoidable limitation in our conclusion is that antihypertensive and 
vasodilating medication was used in almost all SSc patients and could have influenced 
vasodilating properties, both endothelium-dependent and endothelium-independent. We 
corrected the data for use of antihypertensive and vasodilating medication in the linear 
regression analysis. Using digital arteriography focal stenosis and occlusions of digital 
arteries have been found in almost all patients with SSc.
32-35
 Finally, a decreased capillary 
density, as seen in the nailfolds of SSc patients, might have contributed to impaired 
vasodilatory responses.
36
 Assessment of capillary density by nailfold capillaroscopy 
together with assessment of skin microcirculation evaluated by iontophoresis of ACh and 
SNP in combination with laser Doppler fluxmetry in SSc patients has not been investigated 
yet. 
The negative correlation between ACh-mediated vasodilation and Modified 
Rodnan skin score is interesting. The iontophoresis probe was placed on the dorsal side of 
the middle phalanx of the third finger, when possible on normal skin. None of the patients 
had an oedematous phase of the disease, but a fibrotic or atrophic skin was present in part 
of our patients with mostly the limited cutaneous subset. Therefore, the question remains 
whether decreased ACh-mediated vasodilation is explained by a decreased diffusion of 
ACh due to sclerodactyly, or by a true fault in the microcirculation of the digits. However, 
the observation that only the ACh-mediated vasodilation and not the SNP-mediated 
vasodilation correlated negatively with the Rodnan skin score, argues against decreased 
diffusion of the drugs as an explanation for the impaired vasodilation, as also has been 
demonstrated by La Civita et al.
6
 
 In conclusion, this study confirms that ACh-mediated (endothelium-dependent) 
vasodilation in patients with SSc is impaired, also after adjustment for cardiovascular risk 
factors, such as age, smoking, blood pressure and dyslipidaemia. A tendency to impaired 
SNP-mediated (endothelium-independent) vasodilation was found after correction for 
confounders. This suggests that, besides endothelial dysfunction, also structural defects or 
functional changes in the arteriolar wall might be present which are due to the disease itself. 
This subject should be further investigated, since early therapeutic intervention in systemic 
sclerosis and Raynaud‟s phenomenon might influence the development of structural defects 
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